Printer Friendly

First Post Thrombotic Syndrome Treated with Veniti's Venous Stent System.

M2 PHARMA-April 22, 2016-First Post Thrombotic Syndrome Treated with Veniti's Venous Stent System

(C)2016 M2 COMMUNICATIONS

- US-based medical device company Veniti, Inc. has announced the successful treatment of the first patient suffering from Post Thrombotic Syndrome associated with venous outflow obstruction with the company's Vici Verto Venous Stent System.

This stent delivery system allows the physician to deploy a venous stent beginning at the peripheral end of the common femoral vein. The stent system received CE Marking on 1 April 2016.

Post Thrombotic Syndrome is a complication of deep vein thrombosis, which affects more than 1.4 MM people across the United States and Western Europe each year.

It is estimated that 20-50% of the people who have had a deep vein thrombosis will develop Post Thrombotic Syndrome2.

Post Thrombotic Syndrome can have devastating, long-term consequences affecting the quality of life for the thousands of people who suffer from the condition.

Symptoms include progressive leg pain and swelling, leg heaviness and skin changes.

Physicians treat the obstructive component of Post Thrombotic Syndrome through minimally-invasive endovascular stenting procedures.

The VIRTUS Trial is being performed under a US Food and Drug Administration Investigational Device Exemption to evaluate the safety and efficacy of the Vici Venous Stent for the treatment of chronic iliofemoral venous outflow obstruction.

Veniti's Vici Venous Stent and Vici Verto Venous Stent were developed specifically for the challenges of treating iliofemoral venous outflow obstruction. Veniti was founded in 2010 and is headquartered in St. Louis, MO, with technical operations in Fremont, CA.

The Vici Venous Stent and Vici Verto Venous Stent are CE marked under the European Medical Devices Directive (93/42/EEC) and commercially available in Europe.

The Vici Venous Stent is approved by the Australian Therapeutic Goods Administration and commercially available in Australia.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2016 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Apr 22, 2016
Words:307
Previous Article:Yabao Pharmaceutical signs strategic partnership with Salus Pharma.
Next Article:US FDA Clears Hologic's 2D/3D Imaging-Guided Dedicated Prone Biopsy System.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters